 BEDFORD, Mass.--BUSINESS WIRE--- OCUL OCUTX--Ocular TherapeutixTM, Inc. NASDAQ: OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced its intention to present data from its Phase 1 clinical trial of OTX-TKI, an axitinib intravitreal implant for the treatment of patients with wet age-related macular degeneration wet AMD and other retinal diseases, at the upcoming Angiogenesis, Exudations, 